Posters
Scientific Presentations
Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial
Conflict of Interest Statement: Dr. Rixe holds a minor (<0.01%) equity interest in Bexion Pharmaceuticals, Inc.